$1.04
+0.01 (+0.97%)
Open$1.04
Previous Close$1.03
Day High$1.06
Day Low$1.02
52W High$3.19
52W Low$0.87
Volume—
Avg Volume238.5K
Market Cap65.45M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,014.4% upside
Current
$1.04
$1.04
Target
$21.99
$21.99
$18.66
$21.99 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 31.19M | 31.61M | 26.89M |
| Net Income | 2.24M | 2.16M | 1.99M |
| Profit Margin | 7.2% | 6.8% | 7.4% |
| EBITDA | 3.54M | 3.42M | 2.98M |
| Free Cash Flow | 1.72M | 2.00M | 2.13M |
| Rev Growth | -3.9% | +21.8% | -6.2% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.12 | -0.42% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.34 | +0.23% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.08 | -0.84% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.02 | +0.40% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $164.26 | +4.86% | 7.7 | 20.98B |